دورية أكاديمية
أعرض في EDS

Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms.

التفاصيل البيبلوغرافية
العنوان: Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms.
المؤلفون: Bertrums EJM; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands., de Kanter JK; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Derks LLM; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Verheul M; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Trabut L; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Roosmalen MJ; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hasle H; Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Antoniou E; Clinic of Pediatrics III, University Hospital of Essen, Essen, Germany.; AML-BFM Study Group, Essen, Germany., Reinhardt D; Clinic of Pediatrics III, University Hospital of Essen, Essen, Germany.; AML-BFM Study Group, Essen, Germany., Dworzak MN; St. Anna Children's Cancer Research Institute, Vienna, Austria.; St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria., Mühlegger N; St. Anna Children's Cancer Research Institute, Vienna, Austria., van den Heuvel-Eibrink MM; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Utrecht University, Utrecht, the Netherlands., Zwaan CM; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands., Goemans BF; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands., van Boxtel R; Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands. R.vanBoxtel@prinsesmaximacentrum.nl.; Oncode Institute, Utrecht, the Netherlands. R.vanBoxtel@prinsesmaximacentrum.nl.
المصدر: Nature communications [Nat Commun] 2024 Jul 17; Vol. 15 (1), pp. 6025. Date of Electronic Publication: 2024 Jul 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Tumor Suppressor Protein p53*/genetics , Li-Fraumeni Syndrome*/genetics , Germ-Line Mutation* , Neoplasms, Second Primary*/genetics, Humans ; Child ; Male ; Female ; Platinum Compounds/therapeutic use ; Adult ; Adolescent ; Whole Genome Sequencing ; Phylogeny ; Child, Preschool ; Antineoplastic Agents/therapeutic use ; Single-Cell Analysis
مستخلص: Therapy-related myeloid neoplasms (t-MN) arise as a complication of chemo- and/or radiotherapy. Although t-MN can occur both in adult and childhood cancer survivors, the mechanisms driving therapy-related leukemogenesis likely vary across different ages. Chemotherapy is thought to induce driver mutations in children, whereas in adults pre-existing mutant clones are selected by the exposure. However, selective pressures induced by chemotherapy early in life are less well studied. Here, we use single-cell whole genome sequencing and phylogenetic inference to show that the founding cell of t-MN in children starts expanding after cessation of platinum exposure. In patients with Li-Fraumeni syndrome, characterized by a germline TP53 mutation, we find that the t-MN already expands during treatment, suggesting that platinum-induced growth inhibition is TP53-dependent. Our results demonstrate that germline aberrations can interact with treatment exposures in inducing t-MN, which is important for the development of more targeted, patient-specific treatment regimens and follow-up.
(© 2024. The Author(s).)
References: Blood. 2021 May 27;137(21):2992-2997. (PMID: 33598691)
Leukemia. 2022 Apr;36(4):1102-1110. (PMID: 34782715)
Bioinformatics. 2019 Nov 1;35(21):4453-4455. (PMID: 31070718)
Haematologica. 2018 Feb;103(2):266-277. (PMID: 29170254)
Nature. 2020 Jul;583(7815):265-270. (PMID: 32581361)
Nat Genet. 2019 Dec;51(12):1732-1740. (PMID: 31740835)
Expert Rev Mol Med. 2020 Jun 08;22:e2. (PMID: 32508294)
Nat Commun. 2024 Jul 17;15(1):6025. (PMID: 39019934)
Blood. 2011 Feb 17;117(7):2137-45. (PMID: 21127174)
Nat Commun. 2021 Feb 12;12(1):985. (PMID: 33579957)
Clin Cancer Res. 2022 Apr 14;28(8):1614-1627. (PMID: 35078859)
J Clin Oncol. 2017 Jul 10;35(20):2288-2298. (PMID: 28530852)
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. (PMID: 28803919)
Nat Protoc. 2018 Jan;13(1):59-78. (PMID: 29215633)
Leukemia. 2020 Jul;34(7):1816-1827. (PMID: 31988438)
Nat Commun. 2016 May 02;7:11383. (PMID: 27136393)
Nature. 2016 Oct 13;538(7624):260-264. (PMID: 27698416)
Oncogene. 2004 Mar 25;23(13):2330-8. (PMID: 14743206)
STAR Protoc. 2022 May 06;3(2):101361. (PMID: 35573477)
J Mol Cell Biol. 2019 Apr 1;11(4):293-305. (PMID: 30508182)
Curr Hematol Malig Rep. 2022 Dec;17(6):254-265. (PMID: 35986863)
Nat Commun. 2020 Jul 17;11(1):3617. (PMID: 32680998)
Nat Genet. 2020 Nov;52(11):1219-1226. (PMID: 33106634)
Blood. 2021 Sep 2;138(9):749-757. (PMID: 33876223)
Nat Commun. 2018 Jan 31;9(1):455. (PMID: 29386642)
Bioinformatics. 2019 Feb 1;35(3):526-528. (PMID: 30016406)
F1000Res. 2022 Apr 13;11:420. (PMID: 35949917)
N Engl J Med. 2015 Dec 10;373(24):2336-2346. (PMID: 26580448)
Nature. 2015 Feb 26;518(7540):552-555. (PMID: 25487151)
Cancer Discov. 2023 Apr 3;13(4):844-857. (PMID: 36751942)
Cell Rep. 2018 Nov 27;25(9):2308-2316.e4. (PMID: 30485801)
Nat Rev Cancer. 2002 Mar;2(3):188-200. (PMID: 11990855)
Nature. 2022 Jun;606(7913):343-350. (PMID: 35650442)
Am J Hum Genet. 2006 Nov;79(5):779-91. (PMID: 17033956)
Bioinformatics. 2014 Oct;30(19):2811-2. (PMID: 24930139)
Gigascience. 2021 Feb 16;10(2):. (PMID: 33590861)
Nat Rev Cancer. 2017 Aug 24;17(9):513-527. (PMID: 28835720)
Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943)
Nat Commun. 2023 Jan 5;14(1):77. (PMID: 36604421)
Nature. 2020 Feb;578(7793):94-101. (PMID: 32025018)
Nature. 2022 Aug;608(7924):724-732. (PMID: 35948631)
Cell Stem Cell. 2018 Feb 1;22(2):157-170. (PMID: 29395053)
Nature. 2019 Nov;575(7781):210-216. (PMID: 31645765)
BMC Genomics. 2020 Mar 14;21(1):230. (PMID: 32171249)
Mol Cancer Res. 2019 Apr;17(4):895-906. (PMID: 30651371)
Cell Death Differ. 2018 Jan;25(1):154-160. (PMID: 29099487)
Cell. 2019 May 2;177(4):821-836.e16. (PMID: 30982602)
Nat Commun. 2019 Oct 8;10(1):4571. (PMID: 31594944)
Cancer Discov. 2022 Aug 5;12(8):1860-1872. (PMID: 35678530)
Nat Med. 2018 Jan;24(1):103-112. (PMID: 29227476)
Nature. 2018 Mar 15;555(7696):321-327. (PMID: 29489754)
Blood. 2000 Oct 15;96(8):2862-9. (PMID: 11023523)
PLoS One. 2015 Dec 30;10(12):e0146021. (PMID: 26717316)
J Vis Exp. 2018 Apr 10;(134):. (PMID: 29708546)
Genome Biol. 2022 Jan 26;23(1):37. (PMID: 35081992)
Nat Genet. 2022 Apr;54(4):492-498. (PMID: 35410377)
Nat Commun. 2021 Aug 10;12(1):4803. (PMID: 34376657)
DNA Repair (Amst). 2020 Oct;94:102905. (PMID: 32818816)
Genes Chromosomes Cancer. 2009 Sep;48(9):806-15. (PMID: 19530238)
Blood. 2023 May 11;141(19):2359-2371. (PMID: 36626250)
Cell Genom. 2023 Aug 23;3(9):100389. (PMID: 37719152)
Bioinformatics. 2010 Mar 15;26(6):841-2. (PMID: 20110278)
Blood. 2020 Jan 2;135(1):41-55. (PMID: 31697823)
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):. (PMID: 34099548)
Genome Res. 2018 May;28(5):654-665. (PMID: 29632087)
J Pediatr Hematol Oncol. 2009 Nov;31(11):803-11. (PMID: 19801947)
معلومات مُعتمدة: 864499 EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
المشرفين على المادة: 0 (Tumor Suppressor Protein p53)
0 (TP53 protein, human)
0 (Platinum Compounds)
0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20240717 Date Completed: 20240717 Latest Revision: 20240720
رمز التحديث: 20240720
مُعرف محوري في PubMed: PMC11255340
DOI: 10.1038/s41467-024-50384-z
PMID: 39019934
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-50384-z